APX3330 Phase I Oncology Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

INDIANAPOLIS, October 28, 2019 (Newswire.com) - Apexian Pharmaceuticals, Inc., a clinical-stage drug development company focused on advancing APX3330 for the treatment of diseases mediated by the APE1/Ref-1 protein, presented additional data on their Phase 1 study using APX3330 in patients with advanced solid tumors. Results of the trial were presented as a talk in the “Spotlight on Proffered Papers: Emerging Data from Phase I Trials of New Molecular Entities” session on Sunday, October 27.

An additional presentation followed in a poster session. The presentations occurred at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) annual international meeting in Boston, MA. The presentation titled “A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor” was presented by Dr. Mark R. Kelley, Chief Scientific Officer of Apexian and Professor of Pediatrics, Indiana University Simon Cancer Center.

“As we continue development of APX3330 for cancer and other indications, we are very pleased to have been selected to present our phase I trial findings in a platform talk and poster presentation,” said Dr. Mark Kelley, Chief Scientific Officer of Apexian. “APX3330 is an oral drug, and we observed a strong safety profile, recommended phase 2 dose, predicted PK and target engagement of APX3330 on APE1/Ref-1 using transcriptome and proteomic analysis of tumors.”

Dr. Richard Messmann, Chief Medical Officer of Apexian added, “The APE1/Ref-1 protein plays a critical role in mediating a variety of diseases. Our phase I data have now confirmed that APX3330 targets the APE1 protein as expected. These findings pave the way toward confirming the utility of APX3330 in treating diseases as diverse as cancer, diabetic retinopathy, and inflammatory bowel disease, all mediated by the APE1/Ref-1 protein."

About Apexian Pharmaceuticals

Apexian Pharmaceuticals is a patient-centered biotechnology company dedicated to developing novel compounds that target the APE1 protein in multiple indications, including cancer.  Apexian’s research is grounded and driven by the belief that “better is always possible.” Please visit www.ApexianPharma.com for more information.

Media Contact:

Email: [email protected]

Roger D. Miller, COO

Telephone: 844-463-3330 x100

Source: Apexian Pharmaceuticals, Inc.